VCs at MedCity INVEST Digital Health said there’s no shortage of interesting digital health companies, even ones that can prove their innovations are effective. The challenge is winning over insurers and physicians, and finding payment models that work.
The healthcare conference, held in a virtual format due to Covid-19, brings together innovative investors across the healthcare spectrum, prominent industry players and the most promising digital health startups.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The San Francisco Bay Area-based company has two programs in clinical development, which aim to provide the benefits of bone marrow transplantation without the potentially fatal complications involved.
Nines, a teleradiology company using machine learning to triage important cases, raised a $16.5 million funding round led by Accel and 8VC.
A mere five months after an FBI raid, the San Francisco startup, once valued at $600 million, has filed for bankruptcy. It will continue to offer its microbiome test while also looking for a buyer.
Here's how the San Francisco company went from being an investor darling valued at $600 million to being under investigation by the FBI for its corporate practices.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The financing, led by Thiel's Founders Fund, will help the company expand its reach into Europe and Asia while building up its manufacturing capabilities.
The company's technology for screening diabetic retinopathy was granted "Breakthrough Device" designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.
The company also appointed to its board former Novartis CEO Joe Jimenez, who was involved with the Swiss drugmaker's hiring of former Trump attorney Michael Cohen.
The company has enrolled nearly 250,000 members across six states so far in 2018. Oscar has also projected sales of more than $1 billion in gross premium revenue.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.